

SEARCH
Saturday, June 22, 2013
BELVIQ (lorcaserin)
Belviq (lorcaserin) side effects: Musculoskeletal pain in 2% of patients vs 1.4% with placebo
Musculoskeletal pain was reported in 2% of patients given the weight loss drug, Belviq (lorcaserin), versus 1.4% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.
Read the entire article | Email this articleBELVIQ (lorcaserin)
Belviq (lorcaserin) can impair memory and attention, and cause confusion, somnolence and fatigue
The weight loss drug, Belviq (lorcaserin), can cause problems with memory and attention as well as confusion, somnolence, and fatigue according to the prescribing Information for the drug.
“In clinical trials of at least one year in duration, impairments in attention and memory were reported adverse reactions associated with 1.9% of patients treated with Belviq (lorcaserin) and 0.5% of patients treated with placebo, and led to discontinuation in 0.3% and 0.1% of these patients, respectively,” notes the prescribing Information for Belviq (lorcaserin).
“Other reported adverse reactions associated with BELVIQ in clinical trials included confusion, somnolence, and fatigue.”
Read the entire article | Email this articleBELVIQ (lorcaserin)
Belviq (lorcaserin) can cause euphoria, hallucination, and dissociation
The weight loss drug, Belviq (lorcaserin), can cause euphoria, hallucination, and dissociation according to the prescribing Information for the drug.
“Events of euphoria, hallucination, and dissociation were seen with BELVIQ at supratherapeutic doses [that is, larger than recommended doses] in short-term studies. In clinical trials of at least 1-year in duration, 6 patients (0.2%) treated with BELVIQ developed euphoria, as compared with 1 patient (<0.1%) treated with placebo,” notes the prescribing Information for Belviq (lorcaserin).
“Doses of BELVIQ should not exceed 10 mg twice a day.
“Some drugs that target the central nervous system have been associated with depression or suicidal ideation.
“Patients treated with BELVIQ should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
“Discontinue BELVIQ in patients who experience suicidal thoughts or behaviors.”
Read the entire article | Email this articleBELVIQ (lorcaserin)
Belviq (lorcaserin) may cause depression or suicidal ideation
The weight loss drug, Belviq (lorcaserin), may cause depression or suicidal ideation according to the prescribing Information for the drug.
“Some drugs that target the central nervous system have been associated with depression or suicidal ideation,” notes the prescribing Information for Belviq (lorcaserin).
“Patients treated with BELVIQ should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
“Discontinue BELVIQ in patients who experience suicidal thoughts or behaviors.”
Read the entire article | Email this articleBELVIQ (lorcaserin)
Belviq (lorcaserin) can decrease white blood cell count
The weight loss drug, Belviq (lorcaserin), can decrease white blood cell count according to the prescribing Information for the drug.
“In clinical trials of at least one year in duration, adverse reactions of decreases in white blood cell count (including leukopenia, lymphopenia, neutropenia, and decreased white cell count) were reported in 0.4% of patients treated with BELVIQ as compared to 0.2% of patients treated with placebo,” notes the prescribing Information for Belviq (lorcaserin).
Read the entire article | Email this articleBELVIQ (lorcaserin)
Belviq (lorcaserin) may increase the risk for pulmonary hypertension
The weight loss drug, Belviq (lorcaserin), may increase the risk for pulmonary hypertension, a rare but lethal disease, according to the prescribing Information for the drug.
“Certain centrally-acting weight loss agents that act on the serotonin system have been associated with pulmonary hypertension, a rare but lethal disease,” notes the prescribing Information for Belviq (lorcaserin).
“Because of the low incidence of this disease, the clinical trial experience with BELVIQ is inadequate to determine if BELVIQ increases the risk for pulmonary hypertension.”
Read the entire article | Email this articleBELVIQ (lorcaserin)
Belviq (lorcaserin) discontinued by patients due to headache, depression and dizziness
The weight loss drug, Belviq (lorcaserin), may increase the risk for pulmonary hypertension, a rare but lethal disease, according to the prescribing Information for the drug.
“In clinical trials of at least one year in duration, 8.6% of patients treated with BELVIQ prematurely discontinued treatment due to adverse reactions, compared with 6.7% of placebo-treated patients,” notes the prescribing Information for Belviq (lorcaserin).
“The most common adverse reactions leading to discontinuation more often among BELVIQ treated patients than placebo were headache (1.3% vs. 0.8%), depression (0.9% vs. 0.5%) and dizziness (0.7% vs. 0.2%).
Read the entire article | Email this article
Wednesday, June 27, 2012
BELVIQ (lorcaserin hydrochloride)
FDA approves new weight loss drug Belviq (lorcaserin hydrochloride) on June 27, 2012
BELVIQ (lorcaserin hydrochloride)
Belviq (lorcaserin) causes weight loss of 3 to 3.7% more than placebo
BELVIQ (lorcaserin hydrochloride)
Belviq (lorcaserin) should be discontinued if patients do not lose at least 5% in 3 months
BELVIQ (lorcaserin hydrochloride)
Belviq (lorcaserin) side effects include headache, dizziness, fatigue, nausea, constipation
- headache
- dizziness
- fatigue
- nausea
- dry mouth, and
- constipation
and side effects in diabetic patients include
- low blood sugar (hypoglycemia)
- headache
- back pain
- cough, and
- fatigue.
This according to the Press Release from the U.S. Food and Drug Administration.
The drug was approved by the FDA on June 27, 2012.
Read the entire article | Email this articleBELVIQ (lorcaserin hydrochloride)
Belviq (lorcaserin) may cause disturbances in attention or memory
BELVIQ (lorcaserin hydrochloride)
Belviq (lorcaserin) may cause serious side effects including serotonin syndrome
BELVIQ (lorcaserin hydrochloride)
Belviq (lorcaserin) should not be used during pregnancy
BELVIQ (lorcaserin hydrochloride)
Belviq (lorcaserin) may cause serious side effects including serotonin syndrome
However, "drug’s manufacturer will be required to conduct six postmarketing studies, including a long-term cardiovascular outcomes trial to assess the effect of Belviq on the risk for major adverse cardiac events such as heart attack and stroke" notes the FDA Press Release.
Read the entire article | Email this articleBELVIQ (lorcaserin hydrochloride)
Symptoms of Serotonin Syndrome include hyperactive, talkativeness, irritability, confusion
- severe excitement
- hypomania (excitability
- hyperactive and
- talkativeness
- quick anger and
- irritability
- decreased need for sleep
- restlessness
- loss of consciousness
- confusion
- disorientation
- anxiety
- agitation
- motor weakness
- muscle spasms
- tremor
- flailing motion of the arms
- hyperreflexia
- impaired ability to coordinate movement
- difficult poorly articulated speech
- incoordination
- elevated body temperature
- shivering
- pupillary dilation
- sweating
- vomiting
- tachycardia (a racing heart)
- muscle twitches or rigidity
- diarrhea
- changes in blood pressure
- and coma.
Page 2 of 2. Go to page < 1 2
QUICKLINKS AND VIEW OPITONS
QUOTE OF THE DAY
Books by Larry Hobbs available on Amazon


© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.